Showing 691-700 of 4705 results for "".
How Incyte Is Following the Science to Address Unmet Needs in Immune-Mediated Skin Conditions
https://practicaldermatology.com/topics/infections-infectious-disease/how-incyte-is-following-the-science-to-address-unmet-needs-in-immune-mediated-skin-conditions/19945/Ahmad Naim, MD, Vice President of US Medical Affairs at Incyte, shares how the company’s discovery expertise in immunology is fueling research aimed at delivering innovative medicines that address the unmet needs of people living with immune-mediated dermatologic conditions, including atopic dermatiDermwire TV Extra: The Global Access to Skin Health Observatory
https://practicaldermatology.com/series/dermwire-tv/global-access-skin-health-observatory/29873/Esther Freeman, MD, PhD, Director of Global Health Dermatology at Massachusetts General Hospital and Harvard Medical School, and Vice Chair of the International Foundation of Dermatology with the International League of Dermatological Societies (ILDS), talks with Practical Dermatology about her workFDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
https://practicaldermatology.com/series/dermwire-tv/fda-approves-eli-lillys-ad-drug-ebglyss-lebrikizumab/28645/In this week's DermwireTV, Andrew F. Alexis, MD, Professor of Clinical Dermatology at Weill Cornell Medical College, discusses the newly approved AD drug lebrikizumab; LEO Pharma announces two major regulatory milestones for its chronic hand eczema (CHE) treatment; and the CMO of Arcutis BioteherapuDermWire TV: Merz Reorganizes; Amzeeq Approved; Restoration Merges with Venus Concept
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-merz-reorganizes-amzeeq-approved-restoration-merges-with-venus-concept/19694/Bob Rhatigan, newly appointed Global Chief Executive Officer of Merz Aesthetics, speaks about Merz reorganization. Amzeeq topical foam (Foamix Pharmaceuticals) approved for inflammatory, non-nodular, moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. FDA acDermWire TV Extra: Dr. Swanson on BPO
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-extra-dr-swanson-bpo/29166/Practical Dermatology Editorial Board member Elizabeth (Lisa) Swanson, MD, FAAD, addresses the recent news involving the safety of benzoyl peroxide products.Engagement: Still Key to Healthcare Marketing in the Digital Age
https://practicaldermatology.com/topics/general-topics/engagement-still-key-to-healthcare-marketing-in-the-digital-age/21671/New economic conditions call for a strategy shift in medical practice management, and new digital opportunities can play an important rolePlanning a Comeback
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/planning-a-comeback/23300/CSF Faculty members open up about how COVID-19 impacted their practices and what they did about it.2024 In Review: This Year's Trends in Dermatology
https://practicaldermatology.com/topics/feature/2024-review-years-trends-dermatology/29886/As the year comes to a close, Practical Dermatology asked Editorial Board members about trends from 2024—what was hot, what was not, new approvals that lived up to the hype, important new research, and other observations from the past year.On Dosage and Diet: Isotretinoin 101
https://practicaldermatology.com/topics/general-topics/on-dosage-and-diet-isotretinoin-101/21445/Isotretinoin is one of the most essential agents in the treatment of acne, but dietary and dosage considerations must be made to maximize efficacy. Author:Joshua Zeichner, MDAI in Derm: Applying New Tech to Your Practice
https://practicaldermatology.com/topics/practice-management/ai-in-derm-applying-new-tech-to-your-practice/24219/It is with great pleasure and enthusiasm that I begin this quarterly column dedicated to the intersection of dermatology and artificial intelligence (AI). I am a board-certified dermatologist currently pursuing a fellowship in Mohs surgery and cosmetic surgery at Northwestern University. As I embark